Waltham’s KACTUS Introduces Ultra-Low Endotoxin KLK1 Proteins
KACTUS, a biotechnology research reagent provider based in Waltham, Massachusetts, announced the commercial availability of ultra-low endotoxin recombinant human kallikrein-1 proteins designed to support ischemic stroke and cardiovascular disease research. Waltham, MA—KACTUS, a biotechnology company located in Waltham, Massachusetts, has […]
Waltham’s KACTUS Introduces Ultra-Low Endotoxin KLK1 Proteins Read More »










